By Colin Kellaher

Bristol-Myers Squibb Co. (BMY) on Tuesday said the U.S. Federal Trade Commission has requested more information as part of its antitrust review of the company's planned $74 billion acquisition of Celgene Corp. (CELG).

The New York biopharmaceutical company said the so-called "second request" from the FTC involves a review of marketed and pipeline products for the treatment of psoriasis.

Bristol-Myers said the companies plan to work with the FTC to show that the deal won't harm competition.

Bristol-Myers said the FTC's request extends the antitrust waiting period for the deal, but said it still expects to complete the Celgene acquisition in the third quarter.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

March 26, 2019 07:42 ET (11:42 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Celgene Charts.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Celgene Charts.